33 citations
,
April 2015 in “Current Opinion in Endocrinology, Diabetes and Obesity” This review discusses the potential persistent adverse effects associated with 5α reductase inhibitor treatment for androgenetic alopecia but provides no new clinical results; it emphasizes the importance of discussing these risks with patients.
23 citations
,
October 2018 in “Expert Opinion on Drug Safety” This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.
October 2024 in “Andrology” This study investigated paternal drug exposure using FDA data and identified significant associations with reproductive health risks, including congenital anomalies linked to immunosuppressive drugs, and emphasized specific risk combinations like biologics and abortion, diazepam and small for date baby, and finasteride and cryptorchidism.
17 citations
,
May 2019 in “Molecules” This study found that domestic temporary hair dyes may pose a health risk due to their cytotoxic effects on human red blood cells and NIH/3T3 cell lines.
2 citations
,
November 2024 in “GSC Biological and Pharmaceutical Sciences” This article outlines the evolving role of cosmetics in enhancing confidence and attractiveness, highlighting their ability to address skin and hair concerns with active ingredient serums.
